Furthermore, we applied GEPIA-combined data from TCGA and GTEx database for analysis to verify this result (Figure 1(c)), which indicated that ADGRD1 was expressed abnormally in BLCA, BRCA, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), COAD, ESCA, KICH, acute myeloid leukemia (LAML), LUAD, LUSC, ovarian serous cystadenocarcinoma (OV), PRAD, READ, skin cutaneous melanoma (SKCM), STAD, testicular germ cell tumors (TGCT), UCEC, and uterine carcinosarcoma (UCS). This evidence concerns the gene ADGRD1 and ovarian serous cystadenocarcinoma.